Show simple item record

dc.contributor.authorDeepak, Bhatt
dc.contributor.authorKaski, Juan Carlos
dc.contributor.authorDelaney, Sean
dc.contributor.authorAlasnag, Mirvat
dc.contributor.authorAndreotti, Felicita
dc.contributor.authorAngiolillo, Dominick J.
dc.contributor.authorFerro, Albert
dc.contributor.authorGorog, Diana
dc.contributor.authorLorenzatti, Alberto
dc.contributor.authorMamas, Mamas A.
dc.contributor.authorMcNeil, John
dc.contributor.authorNicolau, José C
dc.contributor.authorSteg, Gabriel Philippe
dc.contributor.authorTamargo, Juan
dc.contributor.authorDoreen, Tan
dc.contributor.authorValgimigli, Marco
dc.date.accessioned2021-07-21T09:43:12Z
dc.date.available2021-07-21T09:43:12Z
dc.date.issued2021-05-15
dc.identifier.citationDeepak , B , Kaski , J C , Delaney , S , Alasnag , M , Andreotti , F , Angiolillo , D J , Ferro , A , Gorog , D , Lorenzatti , A , Mamas , M A , McNeil , J , Nicolau , J C , Steg , G P , Tamargo , J , Doreen , T & Valgimigli , M 2021 , ' Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention ' , International Journal of Cardiology , vol. 337 , pp. 1-8 . https://doi.org/10.1016/j.ijcard.2021.05.012
dc.identifier.issn0167-5273
dc.identifier.otherPURE: 25181535
dc.identifier.otherPURE UUID: 6aaafcb3-dc6f-4547-91e0-7c9b543b138f
dc.identifier.otherScopus: 85106876946
dc.identifier.urihttp://hdl.handle.net/2299/24874
dc.description© 2021 The Author(s). Published by Elsevier B.V. his is an open access article under the CC BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.description.abstractAims: Choosing an antiplatelet strategy in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) at high bleeding risk (HBR), undergoing post-percutaneous coronary intervention (PCI), is complex. We used a unique open-source approach (crowdsourcing) to document if practices varied across a small, global cross-section of antiplatelet prescribers in the post-PCI setting. Methods and results: Five-hundred and fifty-nine professionals from 70 countries (the ‘crowd’) completed questionnaires containing single- or multi-option and free form questions regarding antiplatelet clinical practice in post-PCI NSTE-ACS patients at HBR. A threshold of 75% defined ‘agreement’. There was strong agreement favouring monotherapy with either aspirin or a P2Y 12 inhibitor following initial DAPT, within the first year (94%). No agreement was reached on the optimal duration of DAPT or choice of monotherapy: responses were in equipoise for shorter (≤3 months, 51%) or longer (≥6 months, 46%) duration, and monotherapy choice (45% aspirin; 53% P2Y 12 inhibitor). Most respondents stated use of guideline-directed tools to assess risk, although clinical judgement was preferred by 32% for assessing bleeding risk and by 46% for thrombotic risk. Conclusion: The crowdsourcing methodology showed potential as a tool to assess current practice and variation on a global scale and to achieve a broad demographic representation. These preliminary results indicate a high degree of variation with respect to duration of DAPT, monotherapy drug of choice following DAPT and how thrombotic and bleeding risk are assessed. Further investigations should concentrate on interrogating practice variation between key demographic groups.en
dc.format.extent8
dc.language.isoeng
dc.relation.ispartofInternational Journal of Cardiology
dc.rightsOpen
dc.subjectAntiplatelet therapy
dc.subjectCrowdsourcing
dc.subjectHigh bleeding risk
dc.subjectNon-ST segment elevation acute coronary syndrome
dc.subjectP2Y receptor inhibitors
dc.subjectPercutaneous coronary intervention
dc.subjectCardiology and Cardiovascular Medicine
dc.titleResults of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous interventionen
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85106876946&partnerID=8YFLogxK
dc.relation.schoolSchool of Life and Medical Sciences
dc.description.versiontypeFinal Published version
dcterms.dateAccepted2021-05-15
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1016/j.ijcard.2021.05.012
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue
herts.rights.accesstypeOpen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record